Early detection and comprehensive care, alongside established and emerging therapies like trans-catheter valve replacement, are essential to reduce the global burden of rheumatic mitral stenosis.
Rheumatic heart disease (RHD) remains a leading cause of mitral stenosis (MS), particularly in developing countries like India, China or countries within Africa. Characterized by a long latent phase after acute rheumatic fever, rheumatic MS often leads to significant morbidity and mortality. This paper explores its epidemiology, natural history, and clinical consequences, including associations with atrial fibrillation, pulmonary hypertension, heart failure, systemic embolism, and infective endocarditis. We review diagnostic tools, particularly echocardiography, and management strategies such as balloon mitral commissurotomy and surgical interventions. Emerging therapies, including lithotripsy-facilitated procedures and trans-catheter valve replacement, offer promise for high-risk patients. Early detection and comprehensive care are essential to reduce the global burden of rheumatic MS.
Ho et al. (Mon,) conducted a review in Rheumatic heart disease and mitral stenosis. Early detection and comprehensive care, alongside established and emerging therapies like trans-catheter valve replacement, are essential to reduce the global burden of rheumatic mitral stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: